To the full analysis
Buyback calculator for Allogene Therapeutics
Allogene Therapeutics stock: key metrics
ALLOAllogene Therapeutics had an operating margin of 0% and a return on invested capital (ROIC) of −94.5% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2017 | no data | no data | no data |
| 2018 | no data | no data | no data |
| 2019 | no data | no data | no data |
| 2020 | no data | no data | no data |
| 2021 | 100.0% | −157.9% | −159.6% |
| 2022 | −9,063.5% | −215,087.2% | −218,214.1% |
| 2023 | 100.0% | −344,986.3% | −344,489.5% |
| 2024 | 100.0% | −1,241,813.6% | −1,170,863.6% |
| 2025 | no data | no data | no data |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2017 | 100.0% | no data | 0.0% |
| 2018 | −30.1% | −40.9% | −27.3% |
| 2019 | −29.3% | −22.3% | −25.7% |
| 2020 | −23.2% | −89.3% | −20.4% |
| 2021 | −19.7% | −33.6% | −17.3% |
| 2022 | −51.0% | −67.0% | −41.4% |
| 2023 | −63.9% | −37.7% | −50.9% |
| 2024 | −61.0% | −38.6% | −46.9% |
| 2025 | −65.3% | −94.5% | −45.9% |
Data status and sources
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.